Latest Oncology News

Neoadjuvant Enfortumab Vedotin May Be an Option for Cisplatin-Ineligible MIBC

May 28th 2022

Ryan Scott

Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

$FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma$

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

Kristi Rosa

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

FDA Approves 2 Frontline Nivolumab-Based Regimens for Unresectable Advanced or Metastatic ESCC

May 27th 2022

Kristi Rosa

The FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status.

Uliledlimab/Toripalimab Combo Demonstrates Efficacy and Safety in Advanced NSCLC

May 27th 2022

Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.

SIR-Spheres® Y-90 Resin Microspheres Provide Increased Survival Benefit in Colorectal Cancer

May 27th 2022

Ashling Wahner

Mike Cusnir, MD, discusses the role of Y-90 maintenance therapy in colorectal cancer and how it can supplement chemotherapy to prolong life and reduce adverse effects.

Latest Oncology Videos

ESR1 Mutations Provide Window Into Breast Cancer Metastasis

Recent Advances in Treatment of ROS1-Rearranged NSCLC

Dr. Yang on the Current Treatment Landscape in MCL

Mechanism of Action of Ruxolitinib

Incorporating ctDNA Into Routine Practice: Clinical Pearls

Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

Dr. Goel on the Need for Diverse Representation in Clinical Trials

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia (AML): Overview

Historical Approaches to the Management of MF

Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

Factors in Selecting Therapy for Myelofibrosis

Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

Updates in Treatment of NSCLC with ALK Rearrangements

Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRC

Dr. Packiam the Investigation of Cabazitaxel Plus Gemcitabine with Pembrolizumab in Urothelial Carcinoma

Dr. Raje on Unmet Needs with CAR T-Cell Therapy in Myeloma

Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

All Oncology News

Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer

May 27th 2022

Ryan Scott

Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.

Vera Bradley Foundation for Breast Cancer Makes $12.5 Million Commitment to Indiana University School of Medicine

May 27th 2022

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

A gift commitment of $12.5 million to Indiana University School of Medicine from the Vera Bradley Foundation for Breast Cancer will support new research to harness immunotherapy for breast cancer treatment.

Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia

May 27th 2022

Chris Ryan

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma

May 27th 2022

Ashling Wahner

Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.

Black Patients Less Likely to Trust Clinical Trials in Breast Cancer

May 26th 2022

Colleen Moretti

Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.

Increased Investment in Public Welfare Improves OS for Black Patients with Cancer

May 26th 2022

Kyle Doherty

Increased spending on state public welfare programs was associated with a higher 5-year overall survival rate among Black patients.

Disparities Remain Regarding Access to Telehealth

May 26th 2022

Ryan McDonald

Disparities in access to telehealth for cancer care were seen across more than 20 tumor types, according to study findings that were presented during a press briefing ahead of the 2022 ASCO Annual Meeting.

Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma

May 26th 2022

Jason Harris

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

Polatuzumab Vedotin Plus R-CHP Approved in Europe for Previously Untreated DLBCL

May 26th 2022

Kristi Rosa

The European Commission has approved the combination of polatuzumab vedotin and rituximab and cyclophosphamide, doxorubicin, and prednisone for use in adult patients with previously untreated diffuse large B-cell lymphoma.

Tarantino Previews Exciting Research in HER2-Low Breast Cancer

May 26th 2022

OncLive Staff

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.

Mount Sinai’s Natasha Kyprianou, MBBS, PhD, to Receive American Urological Association’s Richard D. Williams, MD, Prostate Cancer Research Excellence Award

May 26th 2022

Tisch Cancer Institute

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association.

Reshaping the Treatment Landscape for Recurrent/Metastatic Nasopharyngeal Carcinoma

May 26th 2022

Brittany Lovely

In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.

NICE Recommends Pembrolizumab Plus Chemotherapy for Metastatic PD-L1–Positive TNBC

May 26th 2022

Jason Harris

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance recommending the approval of pembrolizumab plus chemotherapy for the treatment of patients with PD-L1–positive metastatic triple-negative breast cancer.

2022 ASCO Meeting Agenda Sets the Stage for the Future of Care

May 25th 2022

Brittany Lovely

The 2022 American Society of Clinical Oncology Annual Meeting returns to Chicago, Illinois, with an agenda highlighting primary outcomes as well as extended follow-up data across malignancies.

FDA Approves Ivosidenib Plus Azacitidine for Newly Diagnosed IDH1-Mutated AML

May 25th 2022

Kristi Rosa

The FDA has approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

See All News